Triple-Drug cocktail plus targeted procedure aims to tame incurable liver cancer
NCT ID NCT07691762
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding three drugs—SHR-8068, adebrelimab, and bevacizumab—to a standard liver-directed procedure (TACE) can better control incurable hepatocellular carcinoma. About 690 adults with liver cancer that cannot be surgically removed will receive either the drug combination or a placebo, alongside TACE. The study measures how long the cancer stays under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-8068, adebrelimab, bevacizumab, and transarterial chemoembolization (TACE)
- What this could lead to
- If successful, this combination could offer a new way to slow or stop the growth of liver cancer that cannot be cured, potentially extending life.
- What could go wrong
- This is an early-phase trial, so the combination may not work better than standard care. Side effects from the drugs and procedure could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital，Fudan University
Shanghai, Shanghai Municipality, 200032, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?